AstraZeneca $AZN is launching a restructuring plan expected to generate $1.5B in annual savings, with up to $2B in one-time costs over the next three years. The company plans to reinvest those savings into its drug pipeline, which currently includes more than 180 projects. The move follows several late-stage clinical trial setbacks and growing competition from generic drugs. AstraZeneca is still targeting $80B in annual revenue and 20 new medicine launches by 2030. Meanwhile, Q3 revenue grew 7% to $16.21B, supported by double-digit growth in oncology, respiratory and immunology, and rare disease treatments.

AstraZeneca Q3 2026 Earnings - Core EPS: $2.79 (est $2.62) - Revenue: $16.21B (est $15.98B) - Core Operating Margin: 36% (est 33.6%) - Imfinzi Revenue: $1.99B (est $1.96B) - Farxiga Revenue: $1.61B - Reconfirms Revenue And Core EPS Guidance

AstraZeneca is considering developing cancer vaccines and jumping into one of the hottest areas of oncology research where questions still remain over how broadly the technology will work

AstraZeneca is readying to file the first of a new portfolio of targeted cancer drugs for regulatory approval, moving to cement its position in one of the fastest-growing corners of the oncology market.